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SARINGAN MAYA BERPROSESAN TINGGI PERENCAT 
UNTUK D-ALANINA -D- ALANINA LIGASE A, Salmonella typhi 
 
ABSTRAK 
 
Salmonella typhi berintangan berganda merupakan ancaman terhadap rawatan deman 
tifoid. Peristiwa ini memerlukan rawatan yang baru untuk merencatkan Salmonella 
typhi. Tujuan utama kajian ini adalah untuk mencari perencat yang berpotensi 
terhadap Salmonella typhi dan memahami ciri-ciri prenecatan tersebut. Kajian ini 
menggunakan daya pemprosesan tinggi saringan maya terhadap D-alanina-D-alanina 
ligase A kepada pangkalan data ZINC untuk mencari sasaran yang mempunyai 
potensi untuk menrencatkan Salmonella typhi. D-alanina-D-alanina ligase A adalah 
sasaran prencatan Salmonella typhi yang baik kerana ia memainkan peranan yang 
penting dalam proses biosintesis peptidoglikan, dan ia juga bukan homolog kepada 
protein manusia. Melalui satu siri analisis seperti analisis pos-penyaringan, pemetaan 
pharmacophore, dan analisis ADME/Tox, didapati bahawa N-[3-(1H-imidazol-1-
yl)propyl]-4-(2-methylbenzoyl)-1H-pyrrole-2-carboxamide (ZINC04025098) 
memiliki sifat-sifat perencatan yang berpotensi terhadap D-alanina-D-alanina Ligase 
A.  
xiv  
HIGH THROUGHPUT VIRTUAL SCREENING FOR 
INHIBITORS OF Salmonella typhi’s D-ALANINE-D-ALANINE 
LIGASE A 
 
ABSTRACT  
Increasing numbers of multi-resistance Salmonella typhi cases poses a huge threat 
especially to ongoing typhoid treatments. This turn of event calls for new treatments 
against Salmonella typhi. The objectives of this study is to identify potential drug 
targeted protein from Salmonella typhi using high throughput virtual screening, and 
to understand the inhibition mechanism between ligand and protein.  This research 
looks into the high throughput virtual screening of D-alanine-D-alanine ligase A 
against the ZINC database for potential inhibitors. D-alanine-D-alanine ligase A is a 
vital enzyme in the peptidoglycan biosynthesis pathway, and being a non-human 
homolog, D-alanine-D-alanine ligase A is a good target for inhibition With a series 
of analytical processes like post-screening analysis, protein-inhibitor interactions via 
pharmacophore mapping, and ADME/Tox properties validation,  the analysis reveals 
that N-[3-(1H-imidazol-1-yl) propyl]-4-(2-methylbenzoyl)-1H-pyrrole-2-
carboxamide (ZINC04025098) is a potential inhibitor for D-alanine-D-alanine ligase 
A. 
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Chapter One 
1.0 Introduction 
 
Typhoid fever is a major health issue around the world. Contraction of typhoid fever 
is due to the ingestion of food and/or water source contaminated by Salmonella typhi.  
Annually, an estimated 17 million people are infected with cases of typhoid, with 
600,000 fatalities (Bhan et al., 2005).   
 
Manifestation of typhoid fever includes symptoms like fever, headache, and 
abdominal pain during the first week. Gastrointestinal symptoms like anorexia, 
nausea, vomiting, and constipation with or without any specific signs. The common 
signs like relative bradycardia, splenomegaly, hepatomegaly, and abdominal 
tenderness may develop in the second week of illness. Other complications like acute 
abdomen, pneumonia, intestinal perforation, psychosis, ataxia, altered sensorium and 
nephritis are likely to develop in third to fourth week of illness.  Other complications 
are difficulty in constipating, diarrhea, enlarged spleen, secondary infection leading 
to meningitis, and probably depression. Initial presentation as acute 
glomerulonephritis is a very rare manifestation of typhoid fever (Sinha et al., 1999).  
 
In general, typhoid is an endemic occurring among poor and developing countries 
due to poor sanitation system and inadequate water supply. In Asia, typhoid 
estimated incidence is around 274 per 100 thousand populations yearly, which 
unfortunately, is the highest, compared to other continents (Kothari et al., 2008).  
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Here in Malaysia, typhoid is a notifiable disease since 1986 under the Communicable 
Disease Control Act (CDC Act 1988)    ("Laws of Malaysia. Act 342 Prevention and 
Control of Infectious Diseases Act 1988."). From the year 1997 to 2007, based on the 
report given by the Ministry of Health Malaysia  ("Malaysia Health 2007. Ministry 
of Health Malaysia"), the total number of cases increase from 701 to 1072, an 
alarming increase in numbers. Between 2001 and 2007, the incidence rates were 
between 1.89 and 4.10 per hundred thousand in a population. There were some 
endemic areas and occasionally epidemics especially in the states of Kelantan and 
Sabah (Shah et al., 2012). 
 
The main prevention of typhoid is by improving hygiene and sanitation. Vaccine for 
the high risk group and population are recommended as well as during the outbreak 
control (World Health Organization 2008). The surveillance system for the control 
and prevention of typhoid is still a huge challenge for local health bodies due to the 
wide range of factors associated with typhoid. There are uncertainties also regarding 
to the distribution of these factors, as well as the magnitude and impact on the 
incidence of typhoid. The association of the environmental factors and the 
distribution of typhoid within the various geographical and spatial factors is one of 
the major gray areas of the typhoid surveillance system. Geographical information 
system (GIS) is a very effective tool used for tracking spatial pattern of typhoid 
distribution. GIS provides maps and plots of cases, and also provides the spatial 
combination of data which includes the socioeconomic, distribution of disease, and 
geographical data such as landscapes, water sources like rivers and lakes, and 
weathers (Shah et al., 2012). 
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A study by (Safian et al., 2008) in a district in Malaysia has shown the existence of 
typhoid clusters between 2001 and 2005. Various factors have been shown to be 
related to typhoid incidence. Poor hygiene and sanitation, unsafe food and water 
have been associated with many studies like ; (Sharma et al., 2009 ), (Bhan et al., 
2005), and (Tran et al., 2005 ) regarding the factors directly related to the 
environment of people, thus contributing to the clustering of typhoid.  
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1.1 Problem Statement 
 
`Chloramphenicol, a type of bacteriostatic antimicrobial or antibiotic, was introduced 
to the treatments against Salmonella enterica serovar Typhi (S.typhi) in 1948; the 
drug was very successful at both clinically and economically at that time against 
typhoid. However, in 1950, two years after the introduction of chloramphenicol, 
sporadic resistance towards the drug was observed, but it was not until 1972 that the 
first outbreak of Chloramphenicol-resistance Salmonella typhi was described. Ever 
since then, drug-resistance of Salmonella typhi has become a clinical issue, however 
this time possessing resistance to multiple drugs (Mirza et al., 1996). 
 
After the deposition of Chloramphenicol, a new antibiotic called Ciprofloxacin 
became the main treatment against Salmonella typhi, for being a better drug 
compared to Chloramphenicol. Yet, ever since the discovery of Salmonella typhi 
being resilient to Ciprofloxacin in the typhoid fever patients, the alternate choice of 
antibiotics left is a drug known as Ceftriaxone (also known as Cefexime). However, 
resilience against Ceftriaxone was reported to the Centre for Drug Control (CDC). 
Side effects have been reported for Ceftriaxone (Threlfall et al., 1992). 
 
Multiple-drug resistance Salmonella typhi poses a huge threat especially to 
treatments on-going in typhoid endemic states in Malaysia. The sudden course of this 
event urges for new researches and discoveries for new potential inhibitors for 
Salmonella typhi, and in hopes of these discoveries, a new, effective, and economical 
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drug against typhoid can be at the disposable to combat against Salmonella typhi 
(Phipps et al., 1991).  
 
Now with the accessibility of large amount of genomic and proteomic data obtained 
from human genome project and via the Salmonella typhi genome, these discoveries 
revolutionize studies and researches of novel drug-design for Salmonella typhi. 
These genomic and proteomic data are main resources for the search of novel drug 
targets or inhibitors in Salmonella typhi. Strategy using subtractive genomic studies 
is applied to Salmonella typhi by assuming that the targets identified in Salmonella 
typhi’s metabolic pathways and mechanisms is essential for Salmonella typhi’s 
survival, which should be part of the replication, survival, and at the same time 
should be absent on humans and doesn’t posess any homologs in humans, therefore 
when an experimental ligand is designed to inhibit possible proteins in Salmonella 
typhi should only target the mechanism and functionality of Salmonella typhi and not 
against humans (Bhawna et al., 2009). Therefore any proteins of interest must be 
screened for any sequence similarity with proteins found inside humans. This ensures 
targeted inhibition against Salmonella typhi’s metabolic pathways and not humans. 
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1.2 Objectives  
The objectives of this research are summarized as below:  
1) To identify potential drug targeted protein from Salmonella typhi. 
2) To identify a possible inhibitor for the targeted protein by virtual screening. 
3) To understand the protein-inhibitor interactions. 
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Chapter Two 
2.0 Literature Review 
 
 
2.1 Salmonella typhi 
 
Salmonella typhi is a group of flagellated, rod-shaped, gram-negative, facultative 
anaerobe bacterium that belongs to the Enterobacteriaceae family. 
Enterobactericiae are pathogenic in nature and is the cause of enteric infections. 
They are named after the scientist Dr. Daniel Salmon who is the first to isolate 
Salmonella choleraesuis from a pig’s intestine. (Pui et al., 2011).  There are 
two major Salmonella species; Salmonella enterica and Salmonella 
bongori  (McClelland et al., 2001). Salmonella enterica subsp. enterica serovar 
Typhi is a human-specific organism that give rise to typhoid fever (Pui et al., 2011). 
 
According to the World Health Organization (WHO) Collaborating Centre, Centers 
for Disease Control and Prevention (CDC) and other organizations, Salmonella 
enterica is divided into six major sub-categories of species, whereby they are defined 
by using roman numeric numbers. Salmonella enterica subspecies I is mainly found 
in mammals and is responsible for around 99% of isolates from clinical samples 
while other subspecies and Salmonella  bongori are mainly found in cold-blooded 
animals and is accounted  for as little as 1% of isolates from clinical samples (Pui et 
al., 2011).  There are 2 major pathogenicity genes (pathogenicity islands) that encode 
the virulence factors of Salmonella spp. That allows the bacteria to invade and infect 
their host organisms. There are two important pathogenicity genes: 
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Salmonella pathogenic gene 1 (pathogenicity island 1) and pathogenic gene 2 
(pathogenicity island 2). These pathogenicity islands encode for two different types 
of effector molecules from the type III secretion systems into the host cell, allowing 
the bacteria to intrude the host cell which then leads to the systemic spreading of the 
bacteria in the host organism. Salmonella enterica subsp. enterica serovar Typhi 
possess multiple fimbriae operons that create extracellular appendages allowing them 
to attach and enter their hosts’ intestinal epithelial cells (Srikanth et al., 2011). 
 
Salmonella typhi is capable of infecting a wide range of hosts. Salmonella typhi 
causes enteric fever via the fecal-oral route, through the consumption of Salmonella 
typhi contaminated food and water. The two main clinical syndromes of Salmonella 
infection are: non-typhoidal salmonellosi, a disease called enteritis which affects the 
gastrointestinal system; and typhoid fever (Layton et al., 2007). Depending on the 
species of Salmonella and the specification of host, the nature and severity of 
diseases varies. There are more than  2500 serotypes of Salmonella, and most reports 
of diseases include complications of symptoms like nausea, vomiting, diarrhea and 
cramps at the abdominal (Layton et al., 2007). 
 
 However, in some immune-compromised individuals a severe bacterial infection can 
result in life-threatening septicemia. Severe typhoid fever is caused by Salmonella 
enterica serovar Typhi (Salmonella typhi), Mortality rates in untreated patients is 
between 10 to 15%. Some patients recuperates but becomes carrier of Salmonella 
typhi. (Layton et al., 2007). 
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2.2 Typhoid Fever  
Typhoid fever is a gastrointestinal infection caused by Salmonella typhi. Salmonella 
typhi, is a highly evolved pathogen that evolved somewhere around  fifty thousand 
years ago (Kidgell et al., 2002), possess mechanisms allowing its’ resilience in its 
human host (Merrell et al., 2004).  
 
Although contaminated food  and water  is the major cause for typhoid fever, other 
factors also play important roles in causing typhoid fever in  different endemic 
settings like  poor sanitation , close contact with typhoid cases or carriers, low level 
of education, large household size, close proximity to water bodies, floods , bad 
personal hygiene, poor life style, and travelling to endemic areas. Weather variables 
such as, rainfall, vapor pressure and temperature also affect the transmission and 
distribution of typhoid infections in human populations (Hornick et al., 1970). 
 
 
 
2.3 Global Burden of Typhoid (Epidemiology) 
 
An estimate of the global burden of typhoid fever shows there are probably 16 
million fresh cases yearly with 600,000 reported of deaths (Geneva, 1996). This data 
was first shown in year of 1984 with similar results from various sources were 
published (Edelman et al., 1986). 
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A research done in 2004 concluded that typhoid fever affected  an estimate of 
21,650,974 victims and resulted in 216,510 of deaths in the 2000, and the 
paratyphoid fever infected 5,412,744 victims (John et al., 2004). This estimation was 
concluded on positive blood culture acquired from studies on 22 population. Still, 
this conclusion was only based on result on a few countries, and only 3 studies 
provided data for the African continent.  
 
Typhoid is an endemic in many developing countries, whereas it is sporadic in most 
developed, industrialized nations with supply of clean drinking water and better 
sanitation (John et al., 2004). The reported estimated victims of typhoid fever 
infection in Africa is 50 in 100,000 people and in Asia is as much as 274 in 100,000 
people. This conclude that even with the multiple environment conditions in different 
parts of Asian and African continent, Salmonella typhi possess the ability to survive 
and thrive in these diverse conditions (John et al., 2004) . 
 
 
 
2.4 Pathogenesis 
 
Salmonella typhi, in contrast to other Salmonella species, the only reservoir for the 
bacteria are human beings, thus the pathogenicity of Salmonella typhi is only specific 
towards humans, which results in typhoid or enteric fever (Zhang et al., 2008). 
Salmonella typhi can survive for long period (several months) in both soil and water. 
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Typhoid fever is transmitted by Salmonella typhi-contaminated water and food in 
endemic areas, and especially by Salmonella typhi carriers handling food in 
developing countries. 
 
Salmonella typhi employs a stealth approach which allows the invasion of the human 
body’s inner tissues and thus prevents the onset of an immediate inﬂammatory 
response of the human host in the human gut. (Merrell et al., 2004). 
 
Salmonella typhi is pathogenic, as the bacteria has multiple of pathogenic factors 
(Giannella, 1996).  These factors are: 
      1)  Ability of cell invasion. 
      2)  A full lipopolysaccharide coating. 
      3)  Ability for intracellular replication. 
      4)  The possibility toxin(s) elaboration.  
 
 
There is a probability  that Salmonella typhi attacks the terminal ileum’s gut mucosa 
via a specialized antigen-forming cell called M-cell, through enterocytes, or via a 
para-cellular route (Kops et al., 1996). The bacteria attaches to the mucus of the 
intestine in the internal ileum using the cystic ﬁbrosis transmembrane conductance 
regulator protein (Lyczak et al., 2001).  Induction of intestinal epithelial cells by 
increasing the level of membrane receptor is an important step in the initial phase of 
the infectious process, which thus enhances the ingestion and sub-mucosal 
translocation of the bacteria. (Lyczak et al., 2002).  
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Salmonella typhi infection causes the influx of peripheral white blood cells into the 
lamina propria. The process is facilitated by secretion of cytokine from the epithelial 
cells triggered by the Salmonella typhi’s lipopolysaccharide. Lipopolysaccharide 
coating triggers the transcription factors of lymphocytes by triggering  a toll-like 
receptor 4 complex in the mammalian toll pathway (Chen et al., 1999, Vazquez-
Torres. et al., 2004).  
 
 The invading Salmonella typhi are engulfed by macrophages, which in turn causes  a 
downstream salmonella- induced caspase-1 mediated apoptosis (Parkhill et al., 
2001 ). Firstly, Salmonella typhi attaches to the lymphoid tissues of the intestine, and 
then they flow inside the mesenteric nodes, the thoracic duct, and finally the blood 
circulation. Salmonella typhi will reach the major organs involve in the reticulo-
endothelial system like the bone-marrow and liver within 24 hours from their 
ingestion, where they will thrive and replicate via mono-cytic lineage (Vazquez-
Torres. et al., 2004). The late stage of the disease (8–14 days after incubation) is 
marked when Salmonella typhi are shed back into the blood circulation.  
 
 
 
2.4.1 Mechanisms of Salmonella typhi evasion of innate immunity 
  
Salmonella typhi utilizes several strategies that to avoid the detection of  the host 
innate immune (Quynth et al., 2010). Successful sequencing of the Salmonella typhi 
genome shows a unique region in the Salmonella typhi genome, the Salmonella 
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pathogenicity island 7 (SPI-7) genes. This SPI-7 genes codes the proteins responsible 
for producing and exporting the Vi-capsular polysaccharide antigen.  
 
The Vi-antigen is responsible for the stealth ability of Salmonella typhi by shielding 
the bacteria from being detected by the human immune response, probably by 
shielding the exposure of the lipopolysaccharide layer. Furthermore the TviA, a SPI-
7-encoded regulatory protein responsible for the expression of the Vi-antigen, 
flagellar motility, and the type 3 secretion system (T3SS) responsible for invasion on 
Salmonella Pathogenicity Island 1, is important for the precise timing of expressing 
the virulence factor in the tract of the gastrointestinal system. These findings 
concludes that TviA-facilitated inhibition of expression of flagellar helps Salmonella 
typhi to avoid being detected. 
 
 
 
2.5 Antimicrobial Resistance 
 
Even though the most potent antibiotics are easily accessible globally, however the 
usage of antimicrobial drugs in some developing countries is confined to those who 
can afford them. The first generation of antibiotics are chloramphenicol, ampicillin, 
co-amoxiclav, erythromycin, co-trimoxazole, gentamicin, tetracycline, and penicillin. 
Drugs like amikacin, cefuroxime, ciprofloxacin, and nalidixic acid are used as 
secondary antibiotics (Hart et al., 1998 ). 
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In the late period of 1987, a typhoid fever outbreak broke out in China. The causing 
isolates of Salmonella typhi are resilient to all the ﬁrst line of antimicrobials. (Fu et 
al., 1989). In between 1989 and 1990, there were reported cases of emergence of 
similar Salmonella typhi isolates from Pakistan, the Arabian Gulf, and India. These 
strains of multidrug resistant Salmonella typhi is now reported throughout the world, 
including Malaysia (Hart et al., 1998 ). 
 
 Multiple antimicrobial resistance of Salmonella tyhi is mediated via pHCM1 
plasmid. The plasmid possess 99% similarity to the sequence of plasmid R27, a type 
of H1 plasmid. An estimated of  74% of the strains from Indo-China, Vietnam shows 
that the outbreak of multidrug-resistant typhoid fever was caused by the cloning of 
Salmonella typhi strains possessing resistance plasmid (Bhan et al., 2005).  
 
Chloramphenicol-resistant Salmonella typhi was reported in the United Kingdom 
within just two years of the satisfactory implementation of chloramphenicol against 
Salmonella typhi (Ryan et al., 1989). Subsequently, isolates of Salmonella typhi 
possessing chloramphenicol resistance genes that are transferable were reported from 
Israel (Sompolinski et al., 1967) and Greece (Kontomichalou 1967). In 1967, two 
strains of Salmonella typhi isolated from Cairo and Aden possess resistance genes of 
tetracycline, chloramphenicol, and ampicillin that are transferable. (Anderson et al., 
1972). However, it was not until 1973 that the epidemics of Salmonella typhi 
possessing antimicrobial resistant genes were reported in Mexico (Olarte. et al., 1973) 
and India (Paniker. et al., 1972). Other epidemics also occurred in Korea (Chun. et 
al., 1977), Peru (Yi et al., 1981), and Vietnam (Butler et al., 1973). Many of these 
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resistant isolates carries resistance genes of sulphonamides, chloramphenicol, 
aminoglycosides, and tetracycline. Then, in the year 1981, soon right after the 
discovery of co-trimoxazole, resistance genes of trimethoprim and chloramphenicol 
that are transferable was found in various isolation of Salmonella typhi (Datta et al., 
1981). 
 
First ever report of multi-drug resistant strains was discovered in 1987 in South-East 
Asia (Ling et al., 1984) and have since dispersed throughout the South-East Asia. 
The prominence of these multi-drug resistant strains in China has then increased 
since 1985 and by the year 1989, 80% of the Salmonella typhi isolates found in 
Shanghai possess multiple drug resilience capability. The resilience towards 
ampicillin, chloramphenicol, trimethoprim, tetracycline, cephazolin, sulphonamides, 
and gentamicin was an encoded 98 MDa plasmid which is transferable (Zhang, 1991). 
In Pakistan on the year of 1987, cases of mullti-drug resistant strains were reported 
(Smego et al., 1988) and have since then increased to almost all of the Salmonella 
typhi isolated (Mirza et al., 1993).  
 
Between 1990 and 1991, all of the 25 multi-drug resistant strains isolates obtained 
from Rawalpindi, Pakistan was found to possess a transferable c. 98 MDa plasmid 
that encodes the resistance against ampicillin, chloramphenicol, trimethoprim, 
tetracycline, sulphamethoxazole and streptomycin, but doesn’t possess the resistance 
gene towards gentamicin (Mirza et al., 1993) and therefore, different from the 
Salmonella typhi isolated in China. By the year 1994, in Quetta, a place located in 
Northern Pakistan, 77% of Salmonella. typhi isolates from human blood possess 
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multi-drug resistant genes and they have represented more than 50% of positive 
blood cultures (Mirza et al., 1995).  
 
In 1990, Salmonella typhi possessing multiple-drug resistance were reported in India 
(Jesudasan et al., 1990) and several isolates possess incH1 plasmids were also 
reported (Threlfall et al., 1992). Multi-drug resistant isolates have also been reported 
in Malaysia (Phipps et al., 1991), Bangladesh (Saha et al., 1994) and Vietnam (Tran 
et al., 2005 ), and the epidemic zone in Asia ranges from Pakistan in the western 
zone to China in the eastern zone. Apart from these endemic zones, there is a 
‘partial-epidemic’ area in the Eastern-Central Asia. Somewhere around 35% of the 
population of the Persian Gulf states are migrant workers, mostly from the 
subcontinent of India and the Eastern Indo-China countries like Myanmar. These 
workers migrate regularly from their mother land and thus importing 70-80% of 
Multi-drug resistant of strains Salmonella typhi to Bahrain, Kuwait (Wallace et al., 
1990), Qatar (Uwaydah et al., 1991) and Oman (Elshaffie et al., 1992). In all these 
regions between 5 to 30% of the Salmonella typhi isolates possess multi-drug 
resistant genes.  
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2.6 Peptidoglycan 
  
Peptidoglycan is an important and unique component of the bacterial cell wall, found 
on the external of all gram-positive and gram-negative bacteria’s cytoplasmic 
membrane (Rogers et al., 1980). The main function of peptidoglycan is to preserve 
the integrity of the cell by withstanding turgor pressure. Inhibition against the 
peptidoglycan biosynthesis via any means like mutation, antibiotic targeting or by 
cell lysis, degradation during cell division will result in lysis of the cell. It also plays 
a major role in the sustaining of a well-structured cell and it functions as a docking 
port for the anchorage other cell enveloping components like various signaling 
proteins (Dramsi et al., 2008 ) and teichoic acids (Francis et al., 2003). 
Peptidoglycan also plays a major role in the growth and dividing process of cells. 
 
 
2.6.1 Chemical structure of peptidoglycan 
 
The structural characteristics of peptidoglycan are the cross-linked linear glycan 
layers (Rogers et al., 1980). The glycan layers are consist of separate cross-linked N-
acetylglucosamine and N-acetylmuramic acid residues linked by beta-1, 4 bonds. 
Each MurNAc residues’ D-lactoyl group is substituted by a peptide stem that 
composed of L-Alanine-sigma-D-Glu-meso- A2pm (or L-Lys)-D- Alanine -D- 
Alanine (A2pm, 2,6-diaminopimelic acid) in nascent peptidoglycan, the last D- 
Alanine residue being lost in the finished linked polypeptide. Cross-linkage of the 
glycan strands reaction initiates in between the carboxyl group of D-Alanine at the 
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4th position and the amino group of the di-amino acid at 3rd position, via a peptide 
bridge linkage. Thus, the physiochemical characteristics of the hetero-polymer 
include multiple bonding between sugar (MurNAc), sigma-bonded D-Glu, of L–D 
(and even D–D) bonds and of non-protein amino acids. 
 
 
 
2.6.2 Biosynthesis of peptidoglycan 
  
The peptidoglycan biosynthesis pathway is a complicated biochemical process 
involving  multiple steps in the cytoplasm and membranes of the bacteria (Heijenoort, 
2001). The complex process involves 20 biochemical reactions includes the 
biosynthesis of precursors of nucleotide, and the biosynthesis of lipid-linked 
polymerization reactions and intermediates. These steps occurs at the internal and 
external side of the cytoplasm. 
 
The cytoplasmic steps can be divided into four sets of reactions: 
1) Biosynthesis of UDP-GlcNAc from fructose-6-phosphate. 
2) Biosynthesis of UDP-MurNAc from UDP-GlcNAc. 
3) Combination of the peptide stem leading to UDP-MurNAc-pentapeptide. 
4)  ‘Side’ or ‘annex’ path- ways of synthesis of D-glutamic acid and the 
dipeptide D-alanyl-D-alanine (Heijenoort, 2001). 
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Initial stage of peptidoglycan biosynthesis is the biosynthesis of the soluble 
precursors of nucleotides, by converting UDP- GlcNAc to UDP-MurNAc-
pentapeptide. This processes of biochemical reaction synthesize peptide mediety is 
catalyzed by the MurC, MurD, MurE and MurF ligases. These ligases are responsible 
for the insertion of , meso-diaminopimelic acid,  D-glutamic acid, L-lysine, and  L-
alanine to UDP-MurNAc (Barreteau. et al., 2008).  
 
The defined form of this peptide and the active sites’ uniqueness of these enzymes 
shows diversities in the bacterial world. Initial steps at the membrane phase begin 
with the transfer of the phospho-MurNAc- penta-peptide mediety from the 
cytoplasmic precursor to the membrane receptor undecaprenyl phosphate (C55-P), a 
process mediated by the transferase MraY possessing a pentapeptide called 
undecaprenyl-pyrophosphoryl-Mur- NAc (lipid1) (Barreteau. et al., 2008).  
 
Then, the transferase MurG facilitates the transport of the GlcNAc mediety from 
UDP- GlcNAc to lipid I bonded with undecaprenyl-pyrophosphoryl- MurNAc-
(pentapeptide)-GlcNAc (lipid II) which, after it travels pass the membrane, it 
becomes the substrate for the polymerization reactions (Heijenoort, 2001). The C55-
P carrier lipid is essential in these cascading process and the C55-P carrier lipid is 
also involves in the biosynthesis of other cell-wall related components (Bouhss. et al., 
2008) . 
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2.6.3 Cross Linking 
 
A major step in peptidoglycan layer assembly and deposition is the subsequent 
enzymatic cross-linking of one peptidoglycan strand to an adjacent another 
peptidoglycan strand.  Although direct cross- in Gram-negative bacteria such as 
Salmonella typhi and Escherichia. coli are  made between C,-e-NH, of a meso-DAP  
residue and  the  penultimate -D-Alanine in a second penta-peptide strand, in Gram-
positive organisms such as Staphylococcus aureus a pentaglycine bridge connects the 
strands (Christopher, 1989). Either way the enzymatic cross-linking reactions are 
trans-peptidations. The new interstrand peptide bond is then joined as the intrastrand 
D-Alanine-D-Alanine bond is then broken (Christopher, 1989).   
 
Not all possible inter-peptide cross-linkages are produced within the peptidoglycan 
layers or between the arrays of peptidoglycan layers, but it is obvious that a 
substantial degree of cross-linking provides mechanical strength and rigidity to the 
peptidoglycan layer (Christopher, 1989).  
 
 D-Alanine is therefore a key molecule in the assembly and cross linking of 
peptidoglycan. Three enzymes are involved in conversion of L- alanine  to D-alanine 
and  its attachment to the UDP-rnuramyl pentapeptide (Christopher, 1989). These 
enzymes are: ATP-dependent D-Ala-D-Ala adding enzyme, Pyridoxal phosphate-
dependent alanine racemase, and ATP-dependent D-Ala-D-Ala ligase. 
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2.6.4 D-Alanine-D-Alanine Ligase A 
 
The enzyme D-alanine-D-alanine ligase A (E.C. 6.3.2.4) plays an essential role in 
biosynthesis of bacterial cell wall by building peptide cross-linkages that 
inadvertently provides the spot for trans-acylation for the cross-liking of the peptide 
scaffold (Ellsworth et al., 1996). Therefore it is essential to evaluate D-alanine-D-
alanine ligase A for possible inhibition, as their inhibition will disrupt the 
biosynthesis of bacterial cell wall, due to their major role in peptidoglycan cross-
linking.  
 
 
2.7 Virtual screening  
 
Drugs that have been created for the past 100 years are known to interact with 
approximately 500 targeted proteins, while 20,000,000 organic compounds are 
synthesized. Also, the genomic and functional genomic projects have produced more 
than 1500 possible drug targets against human diseases (Andrew et al., 2002). Thus, 
there are no doubts there are possible drugs (leads or hits), are hidden away in the 
many database. 
 
However, the process in search of these possible leads is very challenging. 
Compiling these compounds and randomly screened them against various proteins 
one by one is very impractical, for it consumes a lot of time, requires lots of 
computing power and thus financially not viable. Yet, virtual screening seems to be 
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the definitive solution, which leads to the development of virtual screening, and 
finally implementing virtual screening into the drug discovery pipeline (Thompson et 
al., 2002).  
 
Virtual screening is designed to search large-scale databases of chemical structures 
or virtual libraries by using multiple computational analysis for selecting a limited 
number of candidate molecules likely to be inhibitive against a chosen biological 
target (Campbell, 2007). Thus, virtual screening is a database searching based on the 
logic expansion of 3D pharmacophore (Ekins et al., 2009) and molecular docking 
(Andrew et al., 2006), allowing automated evaluation of huge databases.  
 
The two methods that are implemented are applying 3D pharmacophore-based 
database searching to locate potential leads from databases and applying molecular 
docking approach to evaluate databases if solved 3D structures of the targets are 
found. Generally, the above are sequential methods, as the first is fast at ﬁltering out 
compounds and the latter has more accurate evaluation of the ligand-receptor 
bindings. Regarding screening based on pharmacophores, a 3D-pharmacophore 
feature is constructed by protein-ligand interaction analysis on a set of active 
compounds (Yasuhisa et al., 2001) or deduction based on the X-ray crystallography 
solved structure of a ligand-receptor complex (Gerhard et al., 2005). By querying 
using 3D–pharmacophore mappings, searching through 3D database  can be 
performed via selection of molecules from available chemical databases, which 
contain pharmacophoric data and follows the pharmacophore geometric restrictions 
(Honglin et al., 2008).  
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Virtual screening based on docking algorithms uses the structural data from both 
receptors and ligands. The concept of docking-based virtual screening consist of 5 
strategies (Honglin et al., 2008):  
1) 3D modeling of receptor  
2) Generation of compound database.  
3) Screening via high processing computers. 
4) Post processing of possible leads 
5) Experimentation of leads via bioassay.  
 
The main strategy of virtual screening is docking and scoring. Docking is a compute 
intensive algorithm that fits 3D compounds into the binding site of a receptor. The 
process optimizes the possible orientations and conformations for a ligand interacting 
with a protein, then select compounds that bind to the protein’s binding pocket in the 
lowest energy conformation. Algorithm of optimizations are used widely by 
molecular docking program and these algorithms are categorized into three main 
groups:  
1)  Numerical optimization algorithms. 
2)  Random/stochastic algorithms. 
3)  Hybrid optimization algorithms.  
Importantly, these are common functions used for scoring docking results (Böhm et 
al., 2003):  
1) Scoring functions based on force-ﬁeld energy. 
2) Scoring functions based on empirical calculations. 
3) Scoring functions based on knowledge.  
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Sadly none of these scoring function can perform perfectly as different system 
calculate differently for physical phenomenon regarding molecular recognition, like 
solvent effects and entropy (Kitchen et al., 2004).  
 
After Kuntz and his colleagues (Kuntz et al., 1982) release to the public the ﬁrst 
docking algorithm, designated as DOCK in the year 1982, more than 20 docking 
algorithm have been created since then. However, there are still many restriction and 
obstacles for molecular docking, such as the accuracy of binding conformation and 
afﬁnity prediction, protein ﬂexibility, entropy, and solvent effects. Molecular 
docking is still a complicated and intriguing topic of bioinformatics (Moitessier et al., 
2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
